Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice

Oncology Research

Volumn 21, Issue 6, 2013, Pages 307-316

  Tao, Yifeng ^a   Lin, Feng ^b   Li, Tao ^a   Xie, Junjie ^a   Shen, Chuan ^a   Zhu, Zhecheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAIZHOU FIRST PEOPLE S HOSPITAL   (China)

Author keywords

CD8+ cytotoxic T lymphocyte (CD8+ CTL); CIITA; Epigenetic modification; Major histocompatability complex II (MHC II); Pancreatic cancer; Vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; ANTIGEN; CYTOKINE; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CARCINOMA CELL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; EPIGENETICS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; COCULTURE; CYTOTOXICITY; DISEASE MODEL; DNA METHYLATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PANCREATIC NEOPLASMS; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TRANS-ACTIVATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929506258     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X13983417587320     Document Type: Article

References (33)

1. Smeenk, H. G.; Tran, T. C.; Erdmann, J.; van Eijck, C. H.; Jeekel, J. Survival after surgical management of pancreatic adenocarcinoma: Does curative and radical surgery truly exist? Langenbecks Arch. Surg. 390:94-103; 2005.
2. Spinelli, G. P.; Zullo, A.; Romiti, A.; Di Seri, M.; Tomao, F.; Miele, E.; Spalletta, B.; Eramo, A.; Hassan, C.; Tomao, S. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP 7:486-491; 2006.
3. Welsch, T.; Kleeff, J.; Friess, H. Molecular pathogenesis of pancreatic cancer: Advances and challenges. Curr. Mol. Med. 7:504-521; 2007.
4. Plate, J. M. Current immunotherapeutic strategies in pancreatic cancer. Surg. Oncol. Clin. N. Am. 16:919-943, xi; 2007.
5. Giarelli, E. Cancer vaccines: A new frontier in prevention and treatment. Oncology (Williston Park) 21:11-18; 2007.
6. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10:909-915; 2004.
7. Diepstra, A.; van Imhoff, G. W.; Karim-Kos, H. E.; van den Berg, A.; te Meerman, G. J.; Niens, M.; Nolte, I. M.; Bastiaannet, E.; Schaapveld, M.; Vellenga, E.; Poppema, S. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J. Clin. Oncol. 25:3101-3108; 2007.
8. Løvig, T.; Andersen, S. N.; Thorstensen, L.; Diep, C. B.; Meling, G. I.; Lothe, R. A.; Rognum, T. O. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br. J. Cancer 87:756-762; 2002.
9. LeibundGut-Landmann, S.; Waldburger, J. M.; Krawczyk, M.; Otten, L. A.; Suter, T.; Fontana, A.; Acha-Orbea, H.; Reith, W. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34:1513-1525; 2004.
10. Reith, W.; Muhlethaler-Mottet, A.; Masternak, K.; Villard, J.; Mach, B. The molecular basis of MHC class II deficiency and transcriptional control of MHC class II gene expression. Microbes Infect. 1:839-846; 1999.
11. Whiteside, T. L.; Gulley, J. L.; Clay, T. M.; Tsang, K. Y. Immunologic monitoring of cellular immune responses in cancer vaccine therapy. J. Biomed. Biotechnol. 2011: 370374; 2011.
12. Armstrong, A. C.; Eaton, D.; Ewing, J. C. Cellular vaccine therapy for cancer. Expert Rev. Vaccines 1:303-316; 2002.
13. Chou, S. D.; Khan, A. N.; Magner, W. J.; Tomasi, T. B. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int. Immunol. 17:1483-1494; 2005.
14. Wright, K. L.; Ting, J. P. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27:405-412; 2006.
15. Emens, L. A.; Jaffee, E. M. Cancer vaccines: An old idea comes of age. Cancer Biol. Ther. 2:S161-S168; 2003.
16. Koido, S.; Homma, S.; Takahara, A.; Namiki, Y.; Tsukinaga, S.; Mitobe, J.; Odahara, S.; Yukawa, T.; Matsudaira, H.; Nagatsuma, K.; Uchiyama, K.; Satoh, K.; Ito, M.; Komita, H.; Arakawa, H.; Ohkusa, T.; Gong, J.; Tajiri, H. Current immunotherapeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 2011:267539; 2011.
17. Stieler, J. Immunotherapeutic approaches in pancreatic cancer. Recent Results Cancer Res. 177:165-177; 2008.
18. Tahvanainen, J.; Pykalainen, M.; Kallonen, T.; Lahteenmaki, H.; Rasool, O.; Lahesmaa, R. Enrichment of nucleofected primary human CD4+ T cells: A novel and efficient method for studying gene function and role in human primary T helper cell differentiation. J. Immunol. Methods 310:30-39; 2006.
19. den Haan, J. M.; Bevan, M. J. A novel helper role for CD4 T cells. Proc. Natl. Acad. Sci. USA 97:12950-12952; 2000.
20. Vigneron, N.; Stroobant, V.; Van den Eynde, B. J.; van der Bruggen, P. Database of T cell-defined human tumor antigens: The 2013 update. Cancer Immun. 13:15; 2013.
21. Ikeda, H. Clinical trials targeting advanced cancers by active immunization of T-cell defined tumor antigens. Curr. Pharm. Design 9:1133-1138; 2003.
22. Van den Eynde, B. J.; van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684-693; 1997.
23. Abbas, A. K.; Murphy, K. M.; Sher, A. Functional diversity of helper T lymphocytes. Nature 383:787-793; 1996.
24. Mosmann, T. R.; Coffman, R. L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173; 1989.
25. Stockinger, B.; Bourgeois, C.; Kassiotis, G. CD4+ memory T cells: Functional differentiation and homeostasis. Immunol. Rev. 211:39-48; 2006.
26. Kharkevitch, D. D.; Seito, D.; Balch, G. C.; Maeda, T.; Balch, C. M.; Itoh, K. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int. J. Cancer 58:317-323; 1994.
27. Poch, B.; Lotspeich, E.; Ramadani, M.; Gansauge, S.; Beger, H. G.; Gansauge, F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch. Surg. 392:353-358; 2007.
28. Atwell, D. M.; Grichnik, K. P.; Newman, M. F.; Reves, J. G.; McBride, W. T. Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. Ann. Thorac. Surg. 66:1145-1150; 1998.
29. Yamamura, M.; Modlin, R. L.; Ohmen, J. D.; Moy, R. L. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 91:1005-1010; 1993.
30. Lopez-Ramirez, M. A.; Male, D. K.; Wang, C.; Sharrack, B.; Wu, D.; Romero, I. A. Cytokine-induced changes in the gene expression profile of a human cerebral microvascular endothelial cell-line, hCMEC/D3. Fluids Barriers CNS 10:27; 2013.
31. Khalil, G.; El-Sabban, M.; Al-Ghadban, S.; Azzi, S.; Shamra, S.; Khalife, S.; Maroun, R. Cytokine expression profile of sensitized human T lymphocytes following in vitro stimulation with amoxicillin. Eur. Cytokine Netw. 19:131-141; 2008.
32. Bellone, G.; Smirne, C.; Mauri, F. A.; Tonel, E.; Carbone, A.; Buffolino, A.; Dughera, L.; Robecchi, A.; Pirisi, M.; Emanuelli, G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol. Immunother. 55:684-698; 2006.
33. Li, M. O.; Flavell, R. A. TGF-beta: A master of all T cell trades. Cell 134:392-404; 2008.